Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.

Oral prednisolone strikes out in children with acute wheeze

25 Nov 2020

Oral prednisolone falls short of improving respiratory outcomes within a day or beyond in preschool children with acute wheeze, a study has shown.

The study included 477 children aged 24–59 months with acute wheeze associated with respiratory illness. These children were randomized to treatment with 2 mg/kg (maximum 40 mg) of oral prednisolone (n=238) or similar placebo (n=239), administered once daily for 3 days.

There was no significant between-group difference observed in the primary outcome of Preschool Respiratory Assessment Measure (PRAM) score 24 hours after intervention (mean difference, −0.39, 95 percent confidence interval [CI], −0.84 to 0.06; p=0.09).

Absolute PRAM score was lower with prednisolone at 4 hours (median, 1 vs 2; p=0.01) and at 24 hours (median, 0 vs 0; p=0.01), although at this time point, symptoms had resolved for most children regardless of initial treatment.

There were fewer children in the active treatment group who received additional oral prednisolone (odds ratio [OR], 0.22) or treatment with intravenous medication (salbutamol, hydrocortisone, magnesium sulphate, or aminophylline; OR, 0.27).

Hospital admission was lower and emergency department stay was shorter in the prednisolone group, although the differences vs placebo were of borderline significance.

Meanwhile, the time it had taken to return to normal activities or rates of representation within 7 days was similar in the two treatment groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.

Audrey Abella, 21 Sep 2020
A single-inhaler triple therapy containing FF/UMEC/VI* may be a good option for COPD** patients who remain symptomatic despite dual bronchodilation with an ICS/LABA or a LAMA/LABA*** and at risk for exacerbations, according to data presented at ERS 2020.